<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567876</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_V-RBAC</org_study_id>
    <nct_id>NCT03567876</nct_id>
  </id_info>
  <brief_title>Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL</brief_title>
  <official_title>Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, phase II trial designed to evaluate whether the addition of&#xD;
      Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with&#xD;
      mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free&#xD;
      Survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to improve long term results of R-BAC, consolidating patients with&#xD;
      high-risk (HR) features (defined as: elevated Ki67 and/or blastoid cytology and/or TP53&#xD;
      mutation after central pathology review) with Venetoclax (ABT-199), which has demonstrated&#xD;
      relevant single agent activity in relapsed/refractory MCL in a Phase 1-2 trial.&#xD;
&#xD;
      The updated Progression Free Survival curves of the R-BAC500 trial has shown that the&#xD;
      expected 2-years PFS for patients with HR disease is 40% (H0), as compared to low-risk&#xD;
      patients (LR) that have a 2-years PFS of 100%. The addition of Venetoclax to HR patients&#xD;
      after R-BAC is expected to improve results and efficacy of this regimen in this &quot;difficult&#xD;
      -to- treat&quot; population, that represents approximately 40-45 % of newly diagnosed elderly&#xD;
      patients with MCL. It appears reasonable to treat with the experimental drug also LR patients&#xD;
      that do not respond appropriately (less than CR) at the end of R-BAC. Since the number of&#xD;
      such LR patients is hardly predictable based on the present experience with R-BAC500 trial,&#xD;
      the analysis of this sub-cohort will be of exploratory nature, and thus assessed separately.&#xD;
&#xD;
      The study objective is to evaluate whether the addition of venetoclax after R-BAC to HR&#xD;
      patients improves the results of the standard R-BAC, in terms of Progression Free Survival .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Actual">July 26, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival of the High Risk patients</measure>
    <time_frame>24 months</time_frame>
    <description>2-years progression-free survival (PFS) of the HR patients from date of enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular response</measure>
    <time_frame>10 months and 30 months</time_frame>
    <description>The proportion of molecular response (analyzed in the labs of the FIL- MRD Network)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of all patients and different subgroups</measure>
    <time_frame>24 months</time_frame>
    <description>The progression-free survival (PFS) of all enrolled patients, and of different subgroups (i.e TP53 mutated patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>54 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of responses</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of complete remission in High Risk and Law Risk patients</measure>
    <time_frame>6 months and 10 months</time_frame>
    <description>The proportion of complete remission (CR) before and after venetoclax in the HR group and/or in the LR not responding to R-BAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completed expected treatment schedule</measure>
    <time_frame>30 months</time_frame>
    <description>The proportion of patients that complete the expected treatment schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>10 months and 30 months</time_frame>
    <description>The proportion of patients with adverse events as assessed by CTCAE 4.03 during venetoclax administration as consolidation or maintenance after R-BAC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Lymphoma, Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>V-RBAC (RBAC followed by Venetoclax)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction phase: RBAC --&gt; up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.&#xD;
Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)</description>
    <arm_group_label>V-RBAC (RBAC followed by Venetoclax)</arm_group_label>
    <other_name>Venclyxto (commercial name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously untreated patients with MCL aged ≥65 years if they are FIT according to the&#xD;
             geriatric CGA assessment.&#xD;
&#xD;
          2. age ≤64 years not eliglible to high-dose chemotherapy plus transplantation at&#xD;
             physician's judgement (details for non eligibility to be recorded by means of the&#xD;
             CIRS, Cumulative Illness rating Scale).&#xD;
&#xD;
          3. Measurable nodal or extranodal disease ≥ 1.5 cm in longest diameter, and measurable in&#xD;
             2 perpendicular dimensions.&#xD;
&#xD;
          4. ECOG performance status ≤2.&#xD;
&#xD;
          5. Positivity for cyclin D1 and/or SOX11 [the latter being mandatory in cases lacking&#xD;
             cyclin D1- or t(11;14)-negative].&#xD;
&#xD;
          6. Adequate renal function (Creatinine clearance &gt;50 mL/min), with preserved diuresis.&#xD;
&#xD;
          7. Adequate liver function: alanine aminotransferase (ALT)/aspartate aminotransferase&#xD;
             (AST) &lt;2.5 x upper limit of normal (ULN) value, total bilirubin &lt;1.5 x ULN, unless&#xD;
             directly attributable to the patient's tumor or to congenital causes.&#xD;
&#xD;
          8. Hepatitis B core antibody (HBcAb) positive/HBsAg negative/HBV-DNA negative patients&#xD;
             may be enrolled if correct antiviral prophylaxis is administered at least 2 weeks&#xD;
             before initiating protocol treatment.&#xD;
&#xD;
          9. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Human immunodeficiency virus (HIV) positive.&#xD;
&#xD;
          2. Previous treatment for lymphoma.&#xD;
&#xD;
          3. Disease confined to the bone marrow/peripheral blood/spleen, without any other nodal&#xD;
             or extranodal involvement.&#xD;
&#xD;
          4. In-situ MCL.&#xD;
&#xD;
          5. Medical conditions or organ injuries that could interfere with administration of&#xD;
             therapy.&#xD;
&#xD;
          6. Active bacterial, viral, or fungal infection requiring systemic therapy.&#xD;
&#xD;
          7. Seizure disorders requiring anticonvulsant therapy.&#xD;
&#xD;
          8. Severe chronic obstructive pulmonary disease with hypoxiemia.&#xD;
&#xD;
          9. History of severe cardiac disease: New York Heart Association (NYHA) functional class&#xD;
             III-IV, myocardial infarction within 6 months, ventricular tachyarrhythmias,&#xD;
             dilatative cardiomyopathy, or unstable angina.&#xD;
&#xD;
         10. Uncontrolled diabetes mellitus.&#xD;
&#xD;
         11. Active secondary malignancy.&#xD;
&#xD;
         12. Known hypersensitivity or anaphylactic reactions to murine antibodies and proteins, to&#xD;
             Bendamustine or mannitol.&#xD;
&#xD;
         13. Major surgery within 4 weeks of study Day 1.&#xD;
&#xD;
         14. HBsAg+&#xD;
&#xD;
         15. HCVAb+ patients with active viral replication (HCV-RNA+ with AST&gt;2 x normal limit)&#xD;
&#xD;
         16. Any co-existing medical or psychological condition that would preclude participation&#xD;
             in the study or compromise the patient's ability to give informed consent, or that may&#xD;
             affect the interpretation of the results, or render the patient at high risk from&#xD;
             treatment complications.&#xD;
&#xD;
         17. CNS involvement&#xD;
&#xD;
         18. Chronic treatment with strong or moderate CYP3A inhibitors (e.g. ketoconazole,&#xD;
             ritonavir, clarithromycin, itraconazole, voriconazole)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Visco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Integrata di Verona - U.O. Ematologia -Verona -Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo, SC Ematologia</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Politecnica delle Marche, Clinica di Ematologia</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico, S.O.C. Oncologia Medica A</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II, UOC Ematologia</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi, Istituto di Ematologia &quot;Seragnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili, Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco, Ematologia</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle, SC Ematologia</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Ematologia</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità di Novara, SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Padova, Ematologia</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo, Divisione di Ematologia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo Da Saliceto, UO Ematologia</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale delle Croci, Ematologia</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi, UO Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I - Università &quot;La Sapienza&quot;, Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica S. Cuore, Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas, UO Ematologia</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino, SC Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino, SC Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca' Foncello, SC Ematologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera C. Panico, UOC Ematologia e Trapianto</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine, Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo, UOC Ematologia</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona, UO Ematologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo, Divisione di Ematologia</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>First line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

